JP2022541646A - 急性神経炎症傷害を処置するための方法および薬剤 - Google Patents

急性神経炎症傷害を処置するための方法および薬剤 Download PDF

Info

Publication number
JP2022541646A
JP2022541646A JP2022505209A JP2022505209A JP2022541646A JP 2022541646 A JP2022541646 A JP 2022541646A JP 2022505209 A JP2022505209 A JP 2022505209A JP 2022505209 A JP2022505209 A JP 2022505209A JP 2022541646 A JP2022541646 A JP 2022541646A
Authority
JP
Japan
Prior art keywords
antibody
sequence
cdr1
seq
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022505209A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022541646A5 (cg-RX-API-DMAC10.html
Inventor
ダブリュー ジーゲラー，ブライアン
ティ クロウ，デイビッド
レウェリン レッドリック，ギャリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Implicit Bioscience Ltd
Original Assignee
Implicit Bioscience Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019902642A external-priority patent/AU2019902642A0/en
Application filed by Implicit Bioscience Ltd filed Critical Implicit Bioscience Ltd
Publication of JP2022541646A publication Critical patent/JP2022541646A/ja
Publication of JP2022541646A5 publication Critical patent/JP2022541646A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2022505209A 2019-07-25 2020-07-24 急性神経炎症傷害を処置するための方法および薬剤 Pending JP2022541646A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019902642 2019-07-25
AU2019902642A AU2019902642A0 (en) 2019-07-25 Methods and agents for treating acute neuroinflammatory injury
PCT/US2020/043619 WO2021016601A1 (en) 2019-07-25 2020-07-24 Methods and agents for treating acute neuroinflammatory injury

Publications (2)

Publication Number Publication Date
JP2022541646A true JP2022541646A (ja) 2022-09-26
JP2022541646A5 JP2022541646A5 (cg-RX-API-DMAC10.html) 2023-07-31

Family

ID=74192699

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022505209A Pending JP2022541646A (ja) 2019-07-25 2020-07-24 急性神経炎症傷害を処置するための方法および薬剤

Country Status (8)

Country Link
US (1) US20220249610A1 (cg-RX-API-DMAC10.html)
EP (1) EP4003518A4 (cg-RX-API-DMAC10.html)
JP (1) JP2022541646A (cg-RX-API-DMAC10.html)
KR (1) KR20220040478A (cg-RX-API-DMAC10.html)
CN (1) CN114450068A (cg-RX-API-DMAC10.html)
AU (1) AU2020316519A1 (cg-RX-API-DMAC10.html)
IL (1) IL290046A (cg-RX-API-DMAC10.html)
WO (1) WO2021016601A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019144141A1 (en) * 2018-01-22 2019-07-25 UNIVERSITY OF VIRGINIA PATENT FOUNDATION d/b/a UNIVERSITY OF VIRGINIA LICENSING & VENTURE System and method for automated detection of neurological deficits
AU2021339468A1 (en) * 2020-09-10 2023-03-30 Implicit Bioscience Limited Therapeutic methods and agents for the treatment of myocardial infarction
US20250212844A1 (en) * 2024-01-02 2025-07-03 Bay West Veterinary Surgery, Inc. Quadruped Lameness Detection using Machine Learning Models

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006129849A1 (ja) * 2005-06-03 2006-12-07 Mochida Pharmaceutical Co., Ltd. 抗ｃｄ１４抗体融合蛋白質
WO2018165720A1 (en) * 2017-03-17 2018-09-20 Implicit Bioscience Pty Ltd Agents for treating or preventing viral infections and uses therefor
WO2018191786A1 (en) * 2017-04-21 2018-10-25 Implicit Bioscience Pty Ltd Cd 14 antagonist antibodies for treating neurodegenerative diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5820858A (en) 1993-05-28 1998-10-13 The Scripps Research Institute Methods and compositions for inhibiting CD14 mediated cell activation
EP1336620A4 (en) 2000-11-22 2004-11-17 Mochida Pharm Co Ltd MONOCLONAL ANTI-CD14 ANTIBODIES INHIBITING THE CD14 / TLR BINDING
WO2006063292A1 (en) 2004-12-08 2006-06-15 Icos Corporation Recombinant method for making multimeric proteins
CA2652815C (en) * 2006-05-25 2015-12-15 Biogen Idec Ma Inc. Methods of treating stroke
WO2008088902A2 (en) * 2007-01-17 2008-07-24 Yale University Attenuation of the adaptive immune response

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006129849A1 (ja) * 2005-06-03 2006-12-07 Mochida Pharmaceutical Co., Ltd. 抗ｃｄ１４抗体融合蛋白質
WO2018165720A1 (en) * 2017-03-17 2018-09-20 Implicit Bioscience Pty Ltd Agents for treating or preventing viral infections and uses therefor
WO2018191786A1 (en) * 2017-04-21 2018-10-25 Implicit Bioscience Pty Ltd Cd 14 antagonist antibodies for treating neurodegenerative diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ACTA NEUROPATHOL, vol. 103, JPN6024024439, 2002, pages 541 - 549, ISSN: 0005491932 *

Also Published As

Publication number Publication date
EP4003518A4 (en) 2023-07-12
CN114450068A (zh) 2022-05-06
IL290046A (en) 2022-03-01
US20220249610A1 (en) 2022-08-11
EP4003518A1 (en) 2022-06-01
AU2020316519A1 (en) 2022-02-24
WO2021016601A1 (en) 2021-01-28
KR20220040478A (ko) 2022-03-30

Similar Documents

Publication Publication Date Title
US8816058B2 (en) Polynucleotides encoding anti-CD100 antibodies or antigen-binding fragments thereof
ES2434470T3 (es) Anticuerpos SP35 y usos de éstos
JP2020143115A (ja) 片頭痛の治療または予防法
JP2023090751A (ja) 神経変性疾患を治療するためのｃｄ１４アンタゴニスト抗体
JP6863892B2 (ja) 脳卒中を治療又は予防する方法
JP2018512435A (ja) Ｇｄｆ８阻害剤を用いて、強度及び機能を増加させる方法
CN103505728A (zh) 用于治疗外伤性脑损伤、脊髓损伤及相关病症的补体旁路抑制
JP2022502417A (ja) 抗ｏｘ４０抗体、その抗原結合フラグメント、および医薬用途
CA2676185A1 (en) Pharmaceutical composition, comprising an anti-cd6 monoclonal antibody used in the diagnosis and treatment of rheumatoid arthritis
JP6865581B2 (ja) 神経学的疾患又は神経変性疾患に有用な新規抗体
KR20230144596A (ko) 항 cd112r 항체 및 그의 용도
US20220249610A1 (en) Methods and agents for treating acute neuroinflammatory injury
KR20230086713A (ko) 안구 질환의 치료를 위한 방법 및 제제
KR20170016501A (ko) 콜로니 자극 인자 1 수용체 (ｃｓｆ1ｒ)에 결합하는 항체를 이용하여 병태를 치료하는 방법
JP2008539266A (ja) 下位運動ニューロン疾患の治療方法およびそれを含む組成物
US20200239562A1 (en) Anti-il-33 therapy for atopic dermatitis
JP7748728B2 (ja) 末梢神経再生を促進するためのｃｘｃｌ１３結合分子の使用
WO2020061571A1 (en) Anti-il-33 antibody for use in treating eosinophilic asthma
KR20210034055A (ko) Htlv-1 관련 척수증(ham) 치료 또는 예방제, 및 ham의 치료 방법
TW201906865A (zh) 預防及治療尿失禁之方法
RU2849860C1 (ru) Применение связывающих cxcl13 молекул для лечения повреждения периферических нервов
WO2014015133A1 (en) Treatment of osteoarthritis using il-20 antagonists
JP2012105657A (ja) ｈＧＭ−ＣＳＦに結合するモノクローナル抗体および前記抗体を含む医薬組成物
EA040534B1 (ru) Способы увеличения безжировой массы тела с помощью антитела к gdf8 или его антигенсвязывающего фрагмента и тренировок с сопротивлением

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230721

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230721

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240625

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240628

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241224